skip to Main Content

Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Based on the GLOBOCAN estimation in 2020, pancreatic cancer is listed the seventh leading cause of death worldwide in both males and females, with the highest incidence rates in Europe and Northern America. Pancreatic cancers are generally classified as endocrine cancer and exocrine cancer, among which pancreatic ductal adenocarcinoma (PDAC) is an exocrine tumor and accounts for around 90% of all malignant pancreatic neoplasms.3 Due to its poor diagnosis and prognosis, the number of deaths resulting from PDAC almost equalizes with the number of cases. According to a report, 458,918 PDAC cases were diagnosed, with 432,242 deaths worldwide in 2018.

A study from 28 European Union countries predicts that pancreatic cancer may become the third leading cause of cancer-related deaths in Europe by 2025.Nowadays surgical treatment, chemotherapy, and radiotherapy are still the routine methods in the clinic. However, surgical resection is reported to be applicable in only 10–15% of patients with PDAC, as most PDAC cases, due to the nonspecific clinical symptoms, are diagnosed at the advanced stage which usually presents widespread metastasis already. Read more . . . 

Back To Top